155 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
29 Jun 22
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
5:17pm
years of healthcare investment banking and corporate finance experience to Ligand.
“Jason is a particularly opportune addition as we begin … financings for Ligand as a senior healthcare investment banker, Jason’s working knowledge of the Ligand business model is deep in experience
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
10 Sep 09
Business Development and Strategic Planning
12:00am
Pharmaceuticals Incorporated (“Ligand”) officers John Higgins and Syed Kazmi gave a presentation at the Thomas Weisel Partners Healthcare Conference … ) Exhibits.
Exhibit No.
Description
Slides used in Ligand’s September 9, 2009 presentation at the Thomas Weisel Partners Healthcare Conference in Boston
8-K
EX-99.2
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
10 Sep 09
Business Development and Strategic Planning
12:00am
Exhibit 99.2
Ligand Pharmaceuticals, Inc.
Thomas Weisel Partners Healthcare Conference 2009
September 9, 2009
Moderator:
Glad to have with us … . The credentials are well laid out, as Syed will talk about a bit more.
Page 1
Ligand Pharmaceuticals, Inc.
Thomas Weisel Partners Healthcare Conference
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
11 Feb 14
Ligand Reports Fourth Quarter and Full Year 2013 Financial Results
12:00am
as the Company’s Vice President of Corporate Development since February 2012. Dr. de Silva has more than thirteen years of healthcare business … experience across healthcare investing and management consulting. Prior to joining the Company, Dr. de Silva worked at the private equity firm Warburg Pincus
425
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
10 Sep 09
Business combination disclosure
12:00am
Pharmaceuticals Incorporated (“Ligand”) officers John Higgins and Syed Kazmi gave a presentation at the Thomas Weisel Partners Healthcare Conference … ) Exhibits.
Exhibit No.
Description
Slides used in Ligand’s September 9, 2009 presentation at the Thomas Weisel Partners Healthcare Conference in Boston
425
q9u369rjica55qnp zao
28 Oct 08
Business combination disclosure
12:00am
425
EX-99.2
emhjndgos4rl cgy
10 Sep 09
Business combination disclosure
12:00am
425
EX-99.2
d0p65i2wuzrznvzpi
23 Mar 22
Business combination disclosure
5:29pm
425
dmd fxjb67knuq8k
4 Nov 08
Business combination disclosure
12:00am
8-K
jfc7pyd4
29 Jun 22
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
5:17pm
8-K
EX-99.2
jl4lmkbgc2ds92
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99
lx31ljap
8 Aug 07
Results of Operations and Financial Condition
12:00am
425
hzhsatq0n0
4 Nov 08
Business combination disclosure
12:00am
425
EX-99.1
a0u5xpxnva
28 Oct 08
Business combination disclosure
12:00am
425
k9am5
28 Oct 08
Business combination disclosure
12:00am
425
EX-99.1
4x6bv
4 Nov 08
Business combination disclosure
12:00am
8-K
EX-99.1
acuu l0mzo
24 Jul 13
Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene
12:00am
425
EX-99.1
nkek ysw0
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
39vna
21 Jun 22
Regulation FD Disclosure
6:19am
425
5biksmh tgyxhbh
26 Aug 09
Business combination disclosure
12:00am